27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Deutsche Bank upgrades Intersect ENT Inc (NASDAQ:XENT) to Buy from Hold after the company made a solid end to 2016 and said the near-term risks related to reimbursement are priced into the shares.
Expansions Ahead
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
“We acknowledge that reimbursement will be worth watching with uncertainty remaining until at least mid-year, however, with 2 product launches, upcoming data publications, and an improving reimbursement profile over the next 12 months, we believe XENT shares will see multiple expansion,” analyst Brittany Henderson wrote in a note.
Notably, Henderson thinks the market should give more credit to the company’s pipeline. Intersect ENT’s first product for the physician's office, PROPEL Contour, received FDA approval in February.
RESOLVE
Further, the company is on track to submit the NDA for RESOLVE, a steroid eluting intranasal implant, by the end of first quarter.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
In fact, Henderson believes RESOLVE represents Intersect ENT’s most exciting pipeline opportunity as it could provide a minimally invasive treatment option for recurrent chronic sinusitis patients who have limited treatment options.
Looking Forward
The analyst still believes 2018 represents a significant year as the company’s physician’s office products are more broadly launched amidst a more favorable reimbursement backdrop.
“Over the next 12 months, we see a host of catalysts that could skew reimbursement more positive including the continued dissemination of the positive ARS position statement, mid 2017 publication of PROPEL Contour data, and YE 2017 publication of RESOLVE clinical trial data,” Henderson added.
At last check, shares of Intersect ENT rose 1.07 percent to $14.15. The analyst also increased her price target to $19 from $15.
Related Link: The Market In 5 Minutes
Related Link: Insulet: 'Results Have Been Stellar But So Has The Share Reaction'27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.